Objectives
The Pathology Unit is committed to advancing animal and human tissue research, focusing on tumor studies.
Areas of impact and applications in the field
The field of pathology, especially in cancer research, conducts essential morphological assessments required for confirming tumor diagnoses and evaluates diagnostic and prognostic parameters of tumors through immunohistochemical methods. A key focus is assessing markers on tumor cells for targetted treatment or treatment planning by providing valuable insights about the interaction between tumor cells and their microenvironment. This unit is also responsible for scoring the targets of newly developed drugs and determining treatment indications, using and developing simple, easily applicable, and measurable pathological methods.
Theranostics, which combines companion diagnostic tools (particularly molecular profiling) with specific therapeutic drugs, allows clinicians to provide patients with personalized therapy based on specific genetic mutations of the tumors. The FDA has dramatically increased the number of cleared/approved in vitro assays for patients with genetic mutations that respond to drugs that prevent the mutations from being expressed, such as tyrosine kinase inhibitors. These alternative forms of therapy have dramatically increased the survival rate in patients with stage four and metastatic cancer.
Pathologists and laboratory experts must determine which companion diagnostic assay should be chosen and recommend the clinically actionable drugs tailored to their genetic mutation to the clinician. This shift in practice presents unprecedented opportunities to diagnose patients and guide the selection of personalized therapies more accurately. As a result, this unit is fundamental for AnkaTheraHub’s development of new anti-tumor drugs.
Services
- Immunohistochemistry IHC – CerbB2
- Accredited Services (Process is ongoing)
- Immunohistochemistry IHC – PD-L1
- Fluorescence In Situ Hybridization FISH
